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Abstract Survivin overexpression, frequently found in
breast cancers and others, is associated with poor progno-
sis. Its dual regulation of cell division and apoptosis makes
it an attractive therapeutic target but its exact functions that
are required for tumor maintenance are still elusive. Sur-
vivin protects cancer cells from genotoxic agents and this
ability is generally assigned to a universal anti-apoptotic
function. However, a specific role in cancer cell protection
from DNA damage has been overlooked so far. We
assessed DNA damage occurrence in Survivin-depleted
breast cancer cells using cH2AX staining and comete
assay. QPCR data and a gene conversion assay indicated
that homologous recombination (HR) was impaired upon
Survivin depletion. We conducted the analysis of Survivin
and HR genes’ expression in breast tumors. We revealed
BRCAness phenotype of Survivin-depleted cells using cell
death assays combined to PARP targeting. Survivin
silencing leads to DNA double-strand breaks in breast
cancer cells and functionally reduces HR. Survivin deple-
tion decreases the transcription of a set of genes involved in
HR, decreases RAD51 protein expression and impairs the
endonuclease complex MUS81/EME1 involved in the
resolution of Holliday junctions. Clinically, EME1,
RAD51, EXO1, BLM expressions correlate with that of
BIRC5 (coding for Survivin) and are of prognostic value.
Functionally, Survivin depletion triggers p53 activation
and sensitizes cancer cells to of PARP inhibition. We
defined Survivin as a constitutive actor of HR in breast
cancers, and implies that its inhibition would enhance cell
vulnerability upon PARP inhibition.
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Introduction
In the last decade, Survivin has attracted considerable
attention as a therapeutic target for anticancer strategies
because of its dual role in regulating cell division and
apoptosis, which are both involved in tumor development
[1]. Survivin is a mitotic protein that associates with
AuroraB kinase, INCENP and borealin to form chromo-
somal passenger complex [2] and also play a role in mitotic
checkpoint as a sensor of kinetochore-microtubule attach-
ment [3]. Survivin promotes cell survival, especially in
cancer cells as part of various molecular networks
encompassing major regulators of apoptosis such as cas-
pases, XIAP and its endogenous inhibitor SMAC [4, 5].
Survivin has been consistently identified as a risk-associ-
ated gene in various malignancies, carrying unfavorable
implications for cancer prognosis, disease recurrence, and
abbreviated survival [6]. Of note, Survivin overexpression
has been identified in breast cancer cells [7] and together
with other gene signatures; this information is now being
used in the clinic for the risk assessment of breast cancer
Electronic supplementary material The online version of this
article (doi:10.1007/s10549-015-3657-z) contains supplementary
material, which is available to authorized users.
& Sophie Barille´-Nion
sophie.barille@inserm.fr
1 CRCNA, UMR INSERM U892/CNRS 6299/Universite´ de
Nantes, Team 8 «Cell survival and tumor escape in breast
cancers», Institut de Recherche en Sante´ de l’Universite´ de
Nantes, 8 quai Moncousu, BP 70721, 44 007 Nantes cedex 1,
France
2 Institut de Cance´rologie de Nantes, Centre de lutte contre le
Cancer Rene´ Gauducheau, Boulevard Jacques Monod,
44 805 Saint-Herblain-Nantes cedex, France
123
Breast Cancer Res Treat (2016) 155:53–63
DOI 10.1007/s10549-015-3657-z
patients [8, 9]. Survivin may play a particular role in
oncogenic processes involved in, at least, the subset of
breast cancers defined as triple negative cancers [10, 11].
Finally, Survivin has been frequently associated with
resistance of cancer cells to chemo- or radiotherapy [12,
13].
Dealing with DNA lesions, such as DNA double-strand
breaks (DSB), is particularly challenging for cancer cells
and their capacity to repair them will finally determine
their fate between survival and death upon overwhelming
DNA damage. Immediately following the generation of a
DSB, a highly conserved DNA damage response (DDR)
pathway is activated to ensure cell survival including halt
cell cycle progression and repair of the lesion. The
molecular DDR begins with the recognition of the DSB
and subsequent activation of the PIKK kinases ATM, ATR,
or DNA-PK, rapidly followed by the recruitment of early
markers such as cH2AX or 53BP1 that will further
nucleate the assembly of various effectors. DSB repair
relies on two major pathways, homologous recombination
(HR) or non-homologous end joining (NHEJ), each with
distinct and overlapping roles in maintaining genomic
integrity. The phosphorylation of the histone variant H2AX
on S139 by activated PIKK kinases is a key initiating step
in the DDR, since it creates an epigenetic signal that
increases DNA accessibility and leads to the recruitment
and accumulation at DNA ends of specific proteins
involved in DDR [14]. The choice between the two main
DSB repair pathways relies on the initial process of DSB
resection which is required for HR but not for NHEJ. DNA
resection comprising the DNA end processing by the MRN
complex in conjunction with the nuclease EXO1 and
auxiliary factors such as 53BP1 or BRCA1, triggers DNA
repair by HR pathway. The RAD51 nucleofilaments then
mediate homology search and strand invasion in the sister
chromatid. After the action of DNA polymerases and
ligases, DNA helicase and resolvase enzymes mediate the
cleavage and resolution of HR intermediates to yield intact
repaired DNA molecules [15].
Previous studies have suggested a link between Survivin
and the DDR. Survivin promotes DNA repair after radia-
tion exposure in glioma [12] and decreases radiation-in-
duced DSB in squamous cell carcinoma cancer cells [16].
In the same line, interference with Survivin results in
reduced DNA repair [17]. These studies report that Sur-
vivin physically interacts with the NHEJ DNA repair
complex thus modulating DNA repair after irradiation but
whether Survivin participates in DNA repair by HR, and by
this way contributes to cell adaptation to genotoxic stress,
remains largely unexplored.
We herein investigated a role of Survivin in genome
maintenance, by specifically studying DNA repair modu-
lation and its consequences in breast cancer cells depleted
in Survivin by RNA interference. Overall, our results
indicate that Survivin is required for efficient DNA repair
by HR and they imply that it participates in cell adaptation
to endogenous genotoxic stress. Importantly, its depletion
creates a state of BRCAness (a phenotype that some tumors
shared with familial-BRCA cancers [18]) that could be
exploited in patients with BRCA-proficient cancer in
combining Survivin and PARP1 inhibitors.
Methods
Cell culture
The human breast cancer cell lines MCF7 and MDAMB-
231 cell lines were purchased from ATCC (Manassas, VA)
and Cal51 cell line from DMSZ (Braunschweig, Germany).
They were maintained in DMEM medium (Invitrogen,
Cergy Pontoise, France) all supplemented with 5 % FCS,
2 mM L-glutamine.
Reagents, antibodies and treatments
z-VAD-fmk was purchased from Promega (Fitchburg,
Wisconsin) and used at 50 lM as 1 h pretreatment prior
transfection and maintained during the experiment. Cis-
platin and Paclitaxel from Sigma-Aldrich were used at
6 lM and 700 nM, respectively.
Survivin antibody was purchased from R&D Systems
(Minneapolis, MN, USA), cH2AX from Upstate (Hamp-
shire, UK), Actin from Chemicon International (Billerica,
MA, USA), RAD51 from Genetex (Irvine, CA, USA),
MUS81 and EME1 from Abcam (Paris, France), p53 from
BD Biosciences (Pont de Claix, France), NOXA from Enzo
Life Science (Villeurbanne, France), BAX from Dako
(Courtaboeuf, France), p21, Ser15 p53, and PUMA from
Cell Signaling (Molsheim, France), CyclinB1 from Santa
Cruz (Heidelberg, Germany). A 2 Gray c-irradiation was
performed using the Faxitron CP160 apparatus and cells
were harvested 30 min after.
Transfection
RNA interference was performed by transfection using
Lipofectamine RNAiMax (Invitrogen, France), according
to the manufacturer’s instructions. The following siRNAs
were used: control siRNA (D-001810) from Dharmacon
(Lafayette, CO, USA), SiRNA Survivin (Ambion), siRNA
CDC20 (4392420) from Life Technologies (Carlsbad, CA,
USA), siRNA BRCA1 (SMARTpool ON-TARGETplus
L-003461), and siRNA AuroraB (SMARTpool ON-
TARGETplus L-003326) from Thermo Fisher Scientific
(Whaltam, MA, USA).
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Plasmids coding for human Survivin or for GFP-fused,
c-terminal fragment of 53BP1 containing both TUDOR and
BRCT domains’ sequences (pG-AcGFP-53BP1c) were
generous gifts from Dr Dario Altieri (Wistar Institute,
Philadelphia, PA, USA) and Dr Thomas Von Zglinicki
(New Castle University, UK), respectively.
Flow cytometry analysis
For cell death assay, cells were analyzed after immunos-
taining using the APO2.7 antibody (Beckman Coulter,
Villepinte, France), according to the manufacturer’s
instructions. For cell cycle analysis, cells were fixed and
permeabilized with ethanol 70 % overnight, then stained
with propidium iodide (PI). Flow-cytometry analysis was
performed on a FACSCalibur using the CellQuestPro
software (Becton–Dickinson, San Jose, CA, USA).
Immunoblot analysis
Cells were resuspended in lysis and sonicated as previously
described [19]. 50 lg of proteins were loaded for each lane
and separated by SDS-PAGE, then electrotransfered to
PVDF membranes. Western blot analysis was performed
by standard techniques with ECL detection (Bio-Rad,
Marne-la coquette, France).
Immunocytochemistry (ICC)
53BP1 expressing Cal51 cells were obtained after transient
transfection using the GFP-53BP1c coding plasmid [20].
They were then plated onto glass coverslip and either
treated by Cisplatin (6 mM) or transfected with siRNA
control or targeting Survivin for 48 h.
For cH2AX staining, cells were seed onto coverslips then
transfected with siRNA (control or Survivin) for 48 h.
Coverslipswere fixed, permeabilized (PBS-1 %SDS10 min)
and blocked. Coverslips were then incubated with the anti-
cH2AX antibody and with goat anti-mouse Alexafluor.
Cells were counterstained with DAPI and images were
viewed on a Zeiss Axiovert 200 M microscope in the
MicroPIcell imaging facility (SFR Bonamy, FED4203/
Inserm UMS 016/CNRS 3556, Nantes, France). Images
were imported into MetaMorph software and cH2AX
scoring was done on the base of a nucleus recognition by
DAPI staining and the score was expressed on cH2AX
threshold area percentage (mean ± SEM).
Recombination assay
RG37 cell line that contains a single copy of a substrate
that specifically monitors gene conversion induced by
double-stranded cut targeted by the meganuclease I-SceI
was a gift from Bernard Lopez (IGR, Paris, France) [21].
RG37cells were first transfected with a I-Sce-I coding
plasmid using jetPEI reagent, then 24 h later, with Sur-
vivin, BRCA1, or control siRNA for 48 h. Expression of a
functional GFP gene reflecting powerful recombination
was then measured by flow cytometry and % of GFP
positive cells and data presented herein correspond to six
independent experiments.
Single cell electrophoresis comet assay
The comet assay was performed in alkaline or neutral
buffer, as previously described [22]. CometSlideTM was
visualized using a Leica microscope, and images were
analyzed into Comet Assay IV software (Perceptive
instruments, Suffolk, UK). The score was expressed on tail
moment with arbitrary units.
RT-qPCR
RNA was isolated from cell lines and 500 ng RNA was
reverse transcribed as previously described [19]. Quanti-
tative PCR was done using the Maxima SYBR Green/ROX
qPCR Master Mix (Life Technologies) and the MX4000
instrument (Stratagene, Basel, Switzerland), according to
the manufacturer’s instructions. The endogenous house-
keeping genes RPLPO, HPRT1, and ACTB1 were used for
normalization. Relative quantification was carried out
using the DDCt method.
Gene expression and statistical analysis
Cancer datasets were downloaded from Breast Cancer Gene-
Expression Miner v3.1 (http://bcgenex.centregauducheau.fr/
BC-GEM/GEM_Accueil.php?js=1) [23, 24].
Statistical analysis
Statistical analysis was performed using paired Student’s
t test on GraphPad Prism. Errors bars represent standard
errors of mean (SEM). The following symbols are used: *,
**, *** that correspond to a p value inferior to 0.05, 0.01,
or 0.001, respectively, and ns for non-statistically
significant.
Results
Survivin depletion in breast cancer cell lines induces
cH2AX activation in response to DSB formation
We first evaluated the impact of Survivin depletion on
DNA damage occurrence in the breast cancer cell lines
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MCF7, MDAMB-231, and Cal51, using the Ser139 phos-
pho-H2AX (cH2AX) marker of DSB either by immunoblot
or by immunofluorescence. Survivin depletion clearly
increased levels of cH2AX compared to the control con-
dition (siCt) in the three cell lines as did the genotoxic
agent cisplatin used as positive control (Fig. 1a). More-
over, cH2AX staining observed upon Survivin depletion,
mainly localized in nuclear foci typical of chromatin-as-
sociated foci observed in DDR, as observed in c irradiated
cells used as positive control (Fig. 1b). cH2AX activation
was also detected in cells transfected with 3 other Survivin
siRNA sequences including 2 targeting the BIRC5 30UTR
sequence (Supplementary Fig. 1 and data not shown).
Importantly, ectopic Survivin reconstitution performed in
rescue experiments using these latter siRNA sequences
could prevent Survivin-depleted cells from DNA damage.
These results clearly eliminated a potential off-target
(Supplementary Fig. 1a). To directly assess DNA breaks,
Survivin-depleted cells were further analyzed in a single
cell gel electrophoresis comet assay in comparison with
siControl cells. As shown in Fig. 1c, Survivin depletion
induced comet formation (in either alcali or neutral lysis
buffer) and significant increase of the tail moment, in a
range comparable to 2 Gray c-irradiation. Finally, a series
of experiments indicate that, the early DNA repair marker
53BP1 localized on nuclear foci in Survivin-depleted cells,
as we described above for cH2AX. Indeed, using engi-
neered cells expressing a GFP-fused 53BP1c protein [20],
Fig. 1 Survivin knockdown induces DNA breaks and DNA damage
response in breast cancer cell lines. DNA damage was evaluated in
breast cancer cells 48 h after Survivin depletion using siRNA by
cH2AX detection by immunoblot (a) and immunocytochemistry
(b) and by single cell comet assay (c). a cH2AX and Survivin
immunoblot analysis of Cal51 cells (left panel) treated by Cisplatin
6 mM (as positive control, lane 2) or not (untreated, lane 1), and
transfected with siRNA control (siControl) (lane 3) or siSurvivin
(lane 4). MDAMB-231 cells (middle panel) and MCF7 cells (right
panel) depleted in Survivin (siSurv) or not (siCt). cH2AX staining by
ICC (b) or single cell gel electrophoresis in alkaline buffer comet
assay (c) were performed in 48 h Survivin-depleted or SiCt
MDAMB-231 cells. 2 Gy-irradiated cells (b and c) were used as
positive control. Representative images are shown (n = 5). Corre-
sponding quantitative comet parameters were calculated using the
comet assay software and comet tail moment was shown in c (below
panel). d GFP nuclear foci were assessed in GFP-53BP1 expressing
Cal51 cells 48 h after Survivin depletion or control. Representative
images are shown in the upper panel. % of positive cells based on
GFP nuclear foci were counted in each condition. Cisplatin treatment
was used as positive control
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GFP nuclear foci could be evidenced in Survivin-depleted
cells compared to control cells, as observed in cisplatin-
treated cells (Fig. 1d).
Eventhough Survivin depletion triggered low if any
apoptosis in the experiments, we nevertheless evaluated
DNA break occurrence in presence of the pan-caspase
inhibitor z-VAD-fmk. This treatment could not signifi-
cantly prevent DSB formation and arguing against a role of
caspases in the generation of DNA breaks (Supplementary
Fig. 1b). These data imply that Survivin depletion induces
accumulation of DSB impacting on early DDR (since early
DNA repair markers are recruited) and independently of an
apoptotic process.
Survivin depletion impairs DNA repair
by homologous recombination
To gain insight into how Survivin depletion triggers DNA
breaks, we examined whether the DNA damage repair is
affected in Survivin-depleted cells. We first evaluated the
transcription of various genes involved in DNA repair
pathways by qPCR after Survivin depletion. We identified
six genes over 19, whose transcription was consistently
impaired in Survivin-depleted cells, namely EME1, BLM,
EXO1, BRCA1, BRCA2, and RAD51 (Fig. 2a). Interest-
ingly, most of them are involved in the homologous
recombination (HR) pathway. To directly assess the impact
of Survivin depletion on HR, we then used a gene con-
version assay based on the RG37 cell line containing a
single chromosomally integrated copy of a GFP substrate
whose conversion following double-stranded cut targeted
by the meganuclease I-Sce-I, monitors the occurrence of
HR [21]. We measured the number of GFP positive cells by
flow cytometry after transfection of I-Sce-I coding plasmid
followed by depletion of Survivin or BRCA1 as positive
control, in RG37 cells, and we found that Survivin deple-
tion repressed gene conversion as efficiently as did BRCA1
depletion (Fig. 2b).
Because RAD51 and EME1/MUS81 support major
activity required in HR, as recombinase and endonuclease,
respectively, we focused our study on these proteins. Using
immunoblot analysis we pointed out that in both cases,
Fig. 2 Survivin silencing impaired DNA repair by homologous
recombination. a qPCR analysis of a set of genes involved in DNA
damage repair in Cal51, MDAMB-231, and MCF7 cells depleted or
not in Survivin. Data are presented as means (±sem) of ratios
normalized to controls from three independent experiments. b HR
activity was evaluated by GFP gene conversion assay using the
genetically modified RG37 cell line. RG37 cells were first transfected
with I-Sce-I coding plasmid, and 24 h later depleted in Survivin or
BRCA1 using specific siRNA. After 48 h, % of GFP positive cells
was assessed in each condition by flow cytometry and presented as
means (±sem) from six independent experiments. c Breast cancer cell
lines were depleted in Survivin (SiSurvivin) or not (SiCt) for 48 h and
immunoblot analysis were performed to evaluate expression of
MUS81/EME1 complex and RAD51 proteins
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their expression was severely impaired upon Survivin
depletion. The RAD51 protein expression decreased upon
Survivin depletion consistently with qPCR results
(Fig. 2c). In contrast, eventhough qPCR data indicated
significant impact of Survivin depletion on EME1 mRNA
level, we could not evidence any substantial decrease of
EME1 protein level in these cells raising the hypothesis
that this protein may be of particular high stability. On the
contrary, MUS81 protein (that carries the nuclease activity
in the complex) was dramatically reduced upon Survivin
depletion in all three cell lines. As qPCR data that did not
detect significant modification of MUS81 mRNA in Sur-
vivin-depleted cells, this suggests post-translational regu-
lation of MUS81 expression in these cells (Fig. 2c).
Collectively, these results strongly argue that Survivin
depletion targets both recombinase and nuclease activity
required during HR, through at least both modulation of
RAD51 and MUS81/EME1 expression.
Prognostic informativity and correlative expression
of BIRC5 and HR genes in primary breast tumors
As our data on cell lines suggest that Survivin expression
influences the expression of HR genes, we investigated
whether the expression of these genes correlate in publi-
cally available data using the Breast Cancer Gene-Ex-
pression Miner v3.1 microarray database and its correlation
module analysis. A gene correlation targeted analysis
between all genes identified above, pointed out significa-
tive linear dependences between BIRC5, EME1, EXO1,
BLM as shown in the correlation map and table corre-
sponding to analysis of all patients, in Fig. 3a and Sup-
plementary Fig. 2a. Altogether, these results from primary
breast tumors corroborate those we revealed using breast
cancer cell lines, and underscore a positive correlation
between the level of expression of BIRC5 and EME1 or
RAD51 or EXO1 mRNA.
Fig. 3 Gene expression analysis of BIRC5 and HR genes in primary
breast tumors. a The correlation map illustrating pairwise correlations
among BIRC5, RAD51, EME1, EXO1, BLM, and BRCA1 genes were
established using the Breast Cancer Gene-Expression Miner v3.1 web
tool. b Kaplan–Meier curves regarding expression of BIRC5, RAD51,
EME1, EXO1, BLM, and BRCA1 genes in tumors from patients with
breast cancer, were established using the Breast Cancer Gene-
Expression Miner v3.1 web tool
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Using the same web tool, we also performed a series of
gene prognostic meta-analysis including BIRC5, EME1,
MUS81, EXO1, RAD51 expression in primary breast
tumors applying a Cox univariate method. As suspected,
BIRC5 expression has a high prognostic informativity
(p\ 0.001) as a pejorative gene in a cohort of 2 413
patients with breast cancer. These results, presented as a
Kaplan–Meier curves in Fig. 3b, indicate that patients with
high BIRC5 expression have a higher risk of metastatic
relapse than those with low BIRC5 expression (Hazard
Ratio HR 1.64 with 95 %CI 1.40–1.92). Interestingly,
RAD51, EME1, EXO1, BLM, and BRCA1 gene expression
also significantly separate cohorts of breast tumors in
patients with low or high risk of metastatic relapse
(Fig. 3b). In contrast, MUS81 gene expression revealed no
prognostic informativity (Supplementary Fig. 2b).
AuroraB depletion more faithfully recapitulates
the effects of Survivin depletion than that of CDC20
In an attempt to determine whether its function as member
of the CPC or its capacity to block cell cycle in G2/M
phase, play a role in Survivin effect on HR, we compared
the effects of its depletion to those of AuroraB or CDC20
depletion. Cell cycle analysis indicates that Survivin
depletion leads to the accumulation of cycling cells in
G2/M phase, as observed in AuroraB-depleted cells
(Fig. 4a). CDC20 depletion also increases cells in G2/M
phase [19]. However, in the case of CDC20 depletion, cells
were blocked in mitosis with accumulation of CyclinB1
protein and CDK1 activity assessed by MPM-2 staining
(Fig. 4b and [19]). In contrast, Survivin or AuroraB-de-
pleted cells mainly exited mitosis without division, in
relation with cytokinesis failure (data not shown).
Expression of HR-related genes, including EME1, EXO1,
BLM, BRCA1, RAD51, MUS81 was quantified by qPCR
analysis in each conditions for the three cell lines and
presented as a heatmap in Fig. 4c. These results show that
AuroraB depletion more closely mimics the effects of
Survivin depletion on gene expression than that of CDC20.
However, since AuroraB depletion potently decreases
BIRC5 expression and vice versa, dissociating their
respective functions is difficult. Collectively, these results
indicate that HR defects detected in Survivin-depleted cells
Fig. 4 AuroraB depletion partially recapitulates the effects of
Survivin depletion on HR genes’ expression a Cell cycle progression
was assessed by PI staining and flow cytometry analysis, in Cal51 and
MDAMB-231 cells upon Survivin (SiSurvivin), AuroraB (SiAuroraB)
depletion. Data are presented as % of cells in cell cycle phases,
obtained at 1, 2, and 3 days after RNA interference. b CyclinB1
expression was studied by immunoblot in Survivin (SiSurvivin),
AuroraB (SiAuroraB), or CDC20 (SiCDC20) depleted cells.
c Expression of HR genes, BIRC5, AURKB, and CDC20 was assessed
by qPCR after Survivin (SiSurvivin), AuroraB (SiAuroraB), or
CDC20 (SiCDC20) depletion. Data are presented as means of ratios
obtained using data from control condition (SiCt) in a heatmap. The
green scale indicates decreased mRNA, and the red scale increased
mRNA. Statistical significativity was indicated as following
***p\ 0.001, **p\ 0.05, *p\ 0.01. (ns not significative)
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better coincides with cytokinesis failure, also observed in
AuroraB-depleted cells, than with mitotic block, as induced
by CDC20 depletion.
Survivin depletion initiates a p53 response
and sensitizes breast cancer cells to PARP inhibitors
Since DNA damage accumulates upon Survivin depletion,
we evaluate whether this coincides with an activation of a
typical p53 response. In unmutated TP53 cancer cells
(Cal51 and MCF7), Survivin depletion led to both p53
protein accumulation and its S15 phosphorylation, as it
could be detected under paclitaxel or cisplatin genotoxic
treatment (Fig. 5a). An increased transcription of p53 tar-
gets, BAX, BBC3 (PUMA), PMAIP1 (NOXA), and
CDKN1A (p21) was detected at mRNA levels as well as
protein levels (except for NOXA) (Fig. 5a–b). These
results argue for the activation of the p53 pathway in
response to DNA damage triggered by Survivin depletion.
Since HR defect may lead to PARP dependency for
DNA repair and subsequently survival, we further
evaluated whether Survivin silencing modifies breast can-
cer cells sensitivity to PARP inhibitors such as olaparib. Of
major importance, combining Survivin depletion and ola-
parib treatment led to significantly increased cell death in
breast cancer cells (Fig. 5c). As expected, this synergic
effect was also detectable when olaparib treatment was
combined to BRCA1 depletion.
Discussion
Survivin regulates multiple intersecting pathways required
for tumor maintenance. Our data show for the first time a
role for Survivin in endogenous DNA damage repair by
HR in cancer cells. We indeed observed that Survivin
participates in the control of HR network, by modulating
protein expression of both main HR actors, the recombi-
nase RAD51 and the nuclease MUS81. Our results are
consistent with the results of a genome-wide siRNA
screen performed in Hela cells that identified Survivin
depletion among other targets, as one of the cause of
Fig. 5 Survivin depletion triggers an active p53 response in p53
proficient cells and modulates response to PARP inhibitors. a and
b DNA damage response including BAX (BAX), NOXA (PMAIP1),
p21(CDKN1A), PUMA (BBC3) p53 targets, was evaluated in Cal51
cells, 48 h after Survivin depletion (SiSurvivin) or not (SiCt), using
either qPCR (a) or immunoblot analysis, this latter including
Paclitaxel (700 nM) or Cisplatin (6 mM) treatments as positive
controls (b). c Survivin depletion sensibilized cancer cells to the
PARP inhibitor Olaparib. MCF7, MDAMB-231 and Cal51 cells were
depleted in Survivin (SiSurvivin) or in BRCA1 (SiBRCA1), as
previously described, and treated with olaparib at the indicated
concentrations, for 4–6 days. Cell death assays were then performed
and analyzed by flow cytometry
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cH2AX activation [25]. Importantly, our results further
revealed that Survivin is required for efficient DNA repair
by HR since its depletion not only decreased the
expression of major actors of DNA repair by HR but also
impaired the gene conversion necessary to its onset.
Recent studies suggest that Survivin modulates the repair
of radiation-induced DSB in supporting the recruitment of
repair proteins to the site of DNA damage and interacts
with the NHEJ pathway [17]. Collectively, these obser-
vations highlight the capability of Survivin to contribute
to DNA repair in cancer cells. In this report, we identified
the recombinase RAD51 and the endonuclease EME1/
MUS81 as major targets controlled by Survivin levels.
Interestingly, the endonuclease activity of the complex is
usually regulated by phosphorylation of its regulatory
subunit EME1 [26]. We provide evidence in this report
that the protein MUS81 can also undergo a strong control
of its expression upon Survivin depletion. To our
knowledge, ubiquitination is the sole modification of
MUS81 that has been reported so far, and this in the
specific context of HIV infection [27]. Since it also plays
a fundamental role in promoting correct chromatid sepa-
ration and mitotic progression [28] defining which
mechanisms govern its expression during cell cycle would
be important to better understand its role in DNA repair
and mitosis progression.
Importantly, meta-analysis of transcriptomic data from
patients with primary breast tumors also reveals not only
that BIRC5 expression significantly correlates with
expression of EME1, EXO1, BLM, RAD51, or BRCA1
genes (HR gene cluster), but also that high expression of
these genes independently associate with pejorative prog-
nosis. In addition, as BIRC5 expression also aggregates
within a proliferation gene cluster [8], our results suggest
that Survivin stands at the cross-road of proliferation and
maintenance of genome integrity. Interestingly, even-
though Survivin does not contain a recognizable DNA
binding domain, its ortholog BIR-1 in C. Elegans can
regulate gene transcription through its effect on histone
phosphorylation [29]. It is in addition puzzling that Sur-
vivin can specifically bind to phosphorylated Histone3
during mitosis [30]. Finally Tang and colleagues proposed
that Survivin acts as a transcription factor or cofactor since
they observed that it binds to CDKN1A promoter where it
interacts with p53 [31]. Thus, this is tempting to speculate
that Survivin may regulate HR genes’ transcription. Further
experiments are needed to validate this hypothesis.
Of note, DSB formation and HR repression upon Sur-
vivin depletion occurred in cells independently of their p53
status. Moreover, Survivin depletion triggered a p53
response in proficient cells. This, coinciding with HR
repression, excludes a global gene transcription repression
upon Survivin silencing.
Finally, we pointed out that Survivin-depleted cells were
prone to cell death when treated by the PARP inhibitor
olaparib, in the same extent as in BRCA1-depleted cells.
We thus provide evidence that Survivin depletion induces
an operative BRCAness phenotype in breast cancer cells
and we propose that combining Survivin targeting with
PARP inhibitors may improve breast cancer therapy and
may benefit to patients without inherited BRCA1/2
mutations.
Prognosis and clinical significance of Survivin in breast
cancers have been recently evaluated based on 23 articles,
revealing overall a higher risk of recurrence and decreased
OS rates in patients with higher Survivin expressing tumors
[32]. In addition, Survivin expression may be predictive of
response to therapy based on various preclinical studies
using organotypic human breast tumors for doxorubicin
treatment [33] or breast cancer cell lines whose in vitro
drug sensitivity was restored by the decrease of Survivin
expression induced by miR-218 targeting [34]. Survivin
also contributes to radioresistance in various preclinical
models of cancers [12, 35, 36]. In this way, clinical use of
so-called Survivin suppressors such as YM155, currently in
clinical trials in cancer therapy [37] or in development
[38], already indicate that YM155 could sensitize cancer
cells to ionizing irradiation [39]. Thus, eventhough recent
reports (reviewed [37]) and our results [40] suggest that
Survivin may not be the only target of this potent cytotoxic
agent, it would be interesting to evaluate YM155 activity
relies at least in part in induction of HR deficiency.
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